| Literature DB >> 34322529 |
Heba Kamel1, Mohamed Saber Hafez1, Islam Bastawy1.
Abstract
Objectives: Telemedicine appears to be a promising tool for healthcare professionals to deliver remote care to patients with cardiovascular diseases especially during the COVID-19 pandemic. We aimed in this study to evaluate the value of telemedicine added to the short-term medical care of acute ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI).Entities:
Keywords: acute coronary syndrome; digital health; drug adherence; major adverse cardiac events; telecardiology; videoconferencing teleconsultations
Year: 2021 PMID: 34322529 PMCID: PMC8311002 DOI: 10.3389/fcvm.2021.693731
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Flow chart of the study. MACE, major adverse cardiac events; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
Comparison of baseline characteristics, MACE, adherence to medications, and lifestyle measures between both groups.
| Age in years (mean ± SD) | 56.2 ± 9.3 | 55.8 ± 11.2 | 0.8 |
| Male gender, % | 73 | 70 | 0.64 |
| HTN, % | 35 | 37 | 0.77 |
| DM, % | 36 | 35 | 0.88 |
| Smoking, % | 72 | 67 | 0.44 |
| IHD, % | 24 | 26 | 0.74 |
| Very low, % | 26 | 24 | 0.92 |
| Low, % | 39 | 41 | |
| Middle, % | 34 | 33 | |
| High, % | 1 | 2 | |
| Overall MACE, % | 11 | 14 | 0.52 |
| Cardiovascular mortality, % | 1 | 2 | 0.56 |
| CVS, % | 1 | 1 | 1 |
| MI, % | 4 | 6 | 0.5 |
| TVR, % | 3 | 6 | 0.3 |
| HF hospitalization, % | 5 | 9 | 0.27 |
| Aspirin, | 96 (96.9%) | 93 (94.9%) | 0.64 |
| P2Y12 inhibitor, | 96 (96.9%) | 93 (93%) | 0.64 |
| Statin, | 86 (86.8%) | 70 (71.4%) | 0.02 |
| BB, | 86 (86.8%) | 80 (81.6%) | 0.51 |
| ACE/ARB, | 62 (83.7%) | 42 (60%) | 0.006 |
| Rehabilitation, | 62 (62.6) | 29 (29.6) | ≤ 0.001 |
| Smoking cessation, | 54 (75%) | 26 (38.8%) | ≤ 0.001 |
HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; CVS, cerebrovascular stroke; TVR, target vessel revascularization; HF, heart failure; MACE, major adverse cardiac events; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BB, B-blockers.
p-value is significant if < 0.05.
Figure 1Patient satisfaction survey.